CanniMed Therapeutics Inc.

The Company is a Canadian-based, international plant biopharmaceutical company and leader in the Canadian medical cannabis industry, with 15 years’ of pharmaceutical cannabis cultivation experience, state-of-the-art, a GMP-compliant production process, including 281 points of quality control and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products.

The Company also has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

Company Beginnings

Company Enters Cannabis Production

Health Canada awarded the Company a five-year, approximately $5.7 million contract to develop comprehensive operations for the growing and cultivation of medical cannabis.

First crops were grown in the biosecure undergrown growth chamber in Flin Flon, Manitoba in 2001, after which time the Company became a Licensed Dealer under the Narcotic Control Regulations and the sole authorized source of dried marijuana for Health Canada under the Marihuana Medical Access Regulations (MMAR).

The Health Canada contract was renewed three times from December 2002 to March 2014.

Research and development programs

CanniMed Therapeutics Inc. Facilities

The Company operates two biosecure growth facilities totalling a combined 247,000 sq. ft.

Facility 1 Saskatoon, Saskatchewan:

97,000 sq. ft. above-ground production facility housing 30 large individual production growth chambers and a total growing capacity of 7,000 kg.

96,000 sq. ft. support building houses the Company’s administrative infrastructure, including laboratories, quality control facilities, maintenance area, a customer care centre and shipping and distribution facilities.

Facility 2 White Pine, Michigan:

35,000 sq. ft. of production and office space; 19,000 sq. ft. of underground growth chambers currently under construction.

The Company constructed its own quality control laboratories and developed and validated various methods of testing cannabinoids, including a first-of-its-kind high-performance liquid chromatography methodology.

The Company is the only Licensed Producer that meets Good Manufacturing Practices standards, which are the same standards and processes that pharmaceutical companies must adhere to in manufacturing their productions in North America.

Medical Cannabis Products

CanniMed Therapeutics Inc. produces seven strains of CanniMed herbal cannabis (dried marijuana) and three varieties of CanniMed cannabis oil. By end of Calendar 2017 the Company will additionally have both Capsules and Topicals on the market.

The Company believes that gelcaps are likely to be more appealing than dried marijuana or bottled oil to physicians and patients, including the largest market segment of baby boomers that are looking for safe and unobtrusive way to manage their chronic pain symptoms and maintain an active lifestyle.

CanniMed Herbal

The CanniMed dried products are not categorized or sold using “street” names often associated with strains marketed by other Licensed Producers. Rather, CanniMed dried cannabis products are identified by the percentage of THC and CBD they contain to better enable physicians to understand dosing regimens and standardize treatments for their patients.

CanniMed Oil

CanniMed cannabis oils are made using only dried cannabis flowers. No leaf, trimming or waste material is used in the Company’s production process. This industry-leading process ensures product consistency, meaning that patients can be confident that each order will be delivered with the same level of active ingredients, allowing them to administer a consistent dose.

Unlike any other cannabis products on the market, CanniMed cannabis oils are made using a food-grade alcohol process, producing a tighter and more segmented cannabinoid profile than can be achieved using CO2 extraction.

CanniMed Capsules

CanniMed has received their license to begin production of CanniMed Capsules, which will on the market for patient purchase by end of calendar 2017. The Company believes that gelcapscapsules are likely to be more appealing than dried marijuana or bottled oil to physicians and patients, including the largest market segment of baby boomers that are looking for safe and unobtrusive way to manage their chronic pain symptoms and maintain an active lifestyle.

The CanniMed® Capsules production facility is fully operational with rated capacity to manufacture 11,000 capsules per hour. This high capacity will enable CanniMed to ensure ample product availability immediately upon the product launch.